Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma

References

• Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer [Internet]. 2022 [cited 2023 Oct 13];128(24):4251–4284. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.34479
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood [Internet]. 2010 [cited 2023 Jul 20];116(19):3724–3734. Available from: https://pubmed.ncbi.nlm.nih.gov/20664057/
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood [Internet]. 2018 [cited 2023 Jul 20];131(25):2745–2760. Available from: https://pubmed.ncbi.nlm.nih.gov/29540348/
   PubMed Web of Science ®Google Scholar
• Wierda WG, Brown J, Abramson JS, et al. NCCN guidelines® insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw [Internet]. 2022 [cited 2023 Jul 20];20(6):622–634. Available from: https://pubmed.ncbi.nlm.nih.gov/35714675/
   PubMed Web of Science ®Google Scholar
• Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med [Internet]. 2023 [cited 2023 Jul 20];388(4):319–332. Available from: https://pubmed.ncbi.nlm.nih.gov/36511784/
   PubMed Web of Science ®Google Scholar
• Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol [Internet]. 2020 [cited 2023 Jul 20];16(10):517–523. Available from: https://pubmed.ncbi.nlm.nih.gov/32207333/
   PubMed Web of Science ®Google Scholar
• Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol [Internet]. 2023 [cited 2023 Oct 11];41(5):1035–1045. Available from: https://pubmed.ncbi.nlm.nih.gov/36395435/
   PubMed Web of Science ®Google Scholar
• Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol [Internet]. 2022 [cited 2023 Oct 11];196(4):947–953. Available from: https://pubmed.ncbi.nlm.nih.gov/34865212/
   PubMed Web of Science ®Google Scholar
• Burger JA, Robak T, Demirkan F, et al. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022;63(6):1375–1386. doi: 10.1080/10428194.2021.2020779
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14(1):14. doi: 10.1038/s41467-023-37648-w
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049–4060. doi: 10.1200/JCO.21.01181
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–1200. doi: 10.1016/S1470-2045(20)30443-5
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol [Internet]. 2017 [cited 2023 Oct 11];35(13):1437. Available from: /pmc/articles/PMC5455463/
   PubMed Web of Science ®Google Scholar
• Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood [Internet]. 2017 [cited 2023 Oct 11];129:1469. Available from: /pmc/articles/PMC5356450/
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. 2022;40:7539–7539 doi: 10.1200/JCO20224016_suppl7539
   Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. doi: 10.1016/S0140-6736(20)30262-2
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia [Internet]. 2022 [cited 2023 Oct 11];36:1171. Available from: /pmc/articles/PMC8979808/
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in Previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–3452. doi: 10.1200/JCO.21.01210
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. Acalabrutinib versus investigator’s choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere [Internet]. 2022 [cited 2023 Oct 11];6(12):E801. Available from: https://pubmed.ncbi.nlm.nih.gov/36398134/
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol [Internet]. 2020 [cited 2023 Oct 11];38(25):2849–2861. Available from: https://pubmed.ncbi.nlm.nih.gov/32459600/
   PubMed Web of Science ®Google Scholar
• Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med [Internet]. 2023 [cited 2023 Oct 11];389:33–44. Available from: https://pubmed.ncbi.nlm.nih.gov/37407001/
   PubMed Web of Science ®Google Scholar
• Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet [Internet]. 2021 [cited 2023 Oct 11];397(10277):892–901. Available from: https://pubmed.ncbi.nlm.nih.gov/33676628/
   PubMed Web of Science ®Google Scholar
• Woyach JA, Flinn IW, Awan FT, et al. Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-Cell malignancies: updated analysis of the open-label phase 1/2 dose-expansion bellwave-001 study. Blood [Internet]. 2022 [cited 2023 Oct 11];140:7004–7006. Available from 10.1182/blood-2022-163596
   Web of Science ®Google Scholar
• Ozcan M, Eradat H, Woyach J, et al. Updated follow-up of BELLWAVE-001: an open-label, single-arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B-cell malignancies. Hematological Oncology [Internet]. 2023 [cited 2023 Oct 11];41(S2):565–567. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3164_423
   Google Scholar
• Aslan B, Hubner SE, Fox JA, et al. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica [Internet]. 2022 [cited 2023 Oct 11];107(1):292–297. Available from: https://pubmed.ncbi.nlm.nih.gov/34498444/
   PubMed Web of Science ®Google Scholar
• Allan JN, Pinilla-Ibarz J, Gladstone DE, et al. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica [Internet]. 2022 [cited 2023 Oct 11];107(4):984–987. Available from: https://pubmed.ncbi.nlm.nih.gov/34937320/
   PubMed Web of Science ®Google Scholar
• Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget [Internet]. 2018 [cited 2023 Oct 11];9(16):13023–13035. Available from: https://pubmed.ncbi.nlm.nih.gov/29560128/
   PubMedGoogle Scholar
• Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022 [cited 2023 Oct 11]; 21:181–200. [Internet]. Available from: https://www.nature.com/articles/s41573-021-00371-6
   PubMed Web of Science ®Google Scholar
• Mato A, Danilov AV, Patel MR, et al. A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies. 2022;40:TPS7581. doi: 10.1200/JCO20224016_supplTPS7581
   Google Scholar
• Mato AR, Wierda WG, Ai WZ, et al. NX-2127-001, a first-in-human trial of NX-2127, a bruton’s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. Blood [Internet]. 2022 [cited 2023 Oct 11];140:2329–2332. Available from 10.1182/blood-2022-164772
   Web of Science ®Google Scholar
• Ailawadhi S, Chen Z, Huang B, et al. Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial. Clin Cancer Res [Internet]. 2023 [cited 2023 Oct 11];29(13):2385–2393. Available from: https://pubmed.ncbi.nlm.nih.gov/37074726/
   PubMed Web of Science ®Google Scholar
• Davids MS, Chanan-Khan A, Mudenda B, et al. Lisaftoclax (APG-2575) safety and activity as monotherapy or combined with acalabrutinib or rituximab in patients (pts) with treatment-naïve, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL): initial data from a phase 2 global study. Blood [Internet]. 2022 [cited 2023 Oct 11];140:2326–2328. Available from 10.1182/blood-2022-160386
   Web of Science ®Google Scholar
• Soumerai JD, Lasica M, Opat S, et al. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Pts) with non-Hodgkin lymphoma (NHL) or waldenström macroglobulinemia (WM): preliminary data. Blood [Internet]. 2022 [cited 2023 Oct 11];140:9325–9327. Available from 10.1182/blood-2022-169664
   Web of Science ®Google Scholar
• Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton’s tyrosine kinase. J Med Chem [Internet]. 2019 [cited 2023 Oct 11];62(17):7923–7940. Available from: https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00687
   PubMed Web of Science ®Google Scholar
• Tam CS, Ou YC, Trotman J, et al. Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14(11):1329–1344. doi: 10.1080/17512433.2021.1978288
   PubMed Web of Science ®Google Scholar
• Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood [Internet]. 2019 [cited 2023 Oct 11];134:851. Available from: /pmc/articles/PMC6742923/
   PubMed Web of Science ®Google Scholar
• Cull G, Burger JA, Opat S, et al. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol [Internet]. 2022 [cited 2023 Oct 11];196(5):1209–1218. Available from: https://pubmed.ncbi.nlm.nih.gov/34915592/
   PubMed Web of Science ®Google Scholar
• Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia [Internet]. 2021. Available from: http://ashpublications.org/blood/article-pdf/137/24/3327/1809937/bloodbld2020009617.pdf
   Google Scholar
• Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results [Internet]. 2020. Available from: http://ashpublications.org/blood/article-pdf/135/15/1204/1723177/blood884940.pdf
   Google Scholar
• Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood [Internet]. 2019 [cited 2023 Oct 13];133:2031–2042. Available from 10.1182/blood-2018-08-870238
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Furman RR, Coutre SE. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):233. doi: 10.1182/blood.V128.22.233.233
   Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica [Internet]. 2018 [cited 2023 Oct 13];103(5):874–879. Available from: https://pubmed.ncbi.nlm.nih.gov/29419429/
   PubMed Web of Science ®Google Scholar
• Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):13. doi: 10.1186/s13045-020-00884-4
   PubMed Web of Science ®Google Scholar
• Xu W, Yang S, Zhou K, et al. Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. Leuk Lymphoma [Internet]. 2023 [cited 2023 Oct 11];64(3):712–716. Available from: https://pubmed.ncbi.nlm.nih.gov/36799536/
   PubMed Web of Science ®Google Scholar
• Shadman M, Munir T, Roback T, et al. ZAnubrutinib (Zanu) versus bendamustine + rituximab (br) in patients (pts) with treatment‐naïve (tn) cll/sll: extended follow‐up of the sequoia study. Hematol Oncol. 2023;41(S2):235–238. doi: 10.1002/hon.3163_154
   Google Scholar
• Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol [Internet]. 2022 [cited 2023 Oct 11];23(8):1031–1043. Available from: https://pubmed.ncbi.nlm.nih.gov/35810754/
   PubMed Web of Science ®Google Scholar
• Tam CS, Robak T, Ghia P, et al. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. Haematologica [Internet]. 2020 [cited 2023 Oct 11];106(9):2354–2363. Available from: https://pubmed.ncbi.nlm.nih.gov/33054121/
   PubMed Web of Science ®Google Scholar
• Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv [Internet]. 2022 [cited 2023 Oct 11];6(4):1296–1308. Available from 10.1182/bloodadvances.2021005621
   PubMed Web of Science ®Google Scholar
• Brown JR, Eichhorst B, Ghia P, et al. P631: characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with b-cell malignancies: post HOC analysis of a large clinical trial safety database. Hemasphere [Internet]. 2023 [cited 2023 Oct 11];7:e356884b. Available from: /pmc/articles/PMC10429013/
   Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med [Internet]. 2014 [cited 2023 Oct 13];371(3):213–223. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1400376
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Owen RG, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia [Internet]. 2021 [cited 2023 Oct 11];35(11):3201–3211. Available from: https://pubmed.ncbi.nlm.nih.gov/33907299/
   PubMed Web of Science ®Google Scholar
• Chen J, Kinoshita T, Gururaja T, et al. The effect of Bruton’s tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK , and tyrosine kinase expressed in hepatocellular carcinoma (TEC). European J Of Haematology [Internet]. 2018 [cited 2023 Oct 11];101(5):604–612. Available from: https://pubmed.ncbi.nlm.nih.gov/30030853/
   Web of Science ®Google Scholar
• Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood [Internet]. 2003 [cited 2023 Oct 11];102(10):3592–3599. Available from: https://pubmed.ncbi.nlm.nih.gov/12842985/
   Google Scholar
• Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Br J Haematol [Internet]. 2019 [cited 2023 Oct 11];184(4):558–569. Available from: https://pubmed.ncbi.nlm.nih.gov/30506764/
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, D’Sa S, et al. Investigators for the A, Opat S. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020 [cited 2023 Oct 11];136(18):2038–2050. doi: 10.1182/blood.2020006844
   PubMed Web of Science ®Google Scholar
• Xiao L, Salem JE, Clauss S, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal src kinase. Circulation [Internet]. 2020 [cited 2023 Oct 11];142(25):2443–2455. Available from: https://pubmed.ncbi.nlm.nih.gov/33092403/
   PubMed Web of Science ®Google Scholar
• Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 [cited 2023 Oct 11];129:2581. Available from:/pmc/articles/PMC7219062/
   PubMed Web of Science ®Google Scholar
• Bhat SA, Gambril J, Azali L, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood [Internet]. 2022 [cited 2023 Oct 11];140:2142–2145. doi: 10.1182/blood.2022016953
   Google Scholar
• Shadman M, Flinn IW, Levy MY, et al. Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed/refractory B-Cell malignancies. Blood. 2021;138(Supplement 1):1410. doi: 10.1182/blood-2021-148544
   Google Scholar
• Eichhorst B, Niemann CU, Kater AP, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023 [cited 2023 Oct 11];388(19):1739–1754. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093
   PubMed Web of Science ®Google Scholar
• Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence [Internet]. 2022 [cited 2023 Oct 11];1(7). Available from: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200006
   Google Scholar
• Soumerai J, Dogan A, Seshan V, et al. Long‐term follow‐up of multicenter phase ii trial of zanubrutinib, obinutuzumab, and venetoclax (BOVEN) in previously untreated patients with CLL/SLL. Hematol Oncol. 2023;41(S2):233–235. doi: 10.1002/hon.3163_153
   Google Scholar
• Meng EC, Goddard TD, Pettersen EF, et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023 [cited 2024 Feb 18];32(11). doi: 10.1002/pro.4792
   PubMed Web of Science ®Google Scholar